<code id='EB59797C88'></code><style id='EB59797C88'></style>
    • <acronym id='EB59797C88'></acronym>
      <center id='EB59797C88'><center id='EB59797C88'><tfoot id='EB59797C88'></tfoot></center><abbr id='EB59797C88'><dir id='EB59797C88'><tfoot id='EB59797C88'></tfoot><noframes id='EB59797C88'>

    • <optgroup id='EB59797C88'><strike id='EB59797C88'><sup id='EB59797C88'></sup></strike><code id='EB59797C88'></code></optgroup>
        1. <b id='EB59797C88'><label id='EB59797C88'><select id='EB59797C88'><dt id='EB59797C88'><span id='EB59797C88'></span></dt></select></label></b><u id='EB59797C88'></u>
          <i id='EB59797C88'><strike id='EB59797C88'><tt id='EB59797C88'><pre id='EB59797C88'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:explore    Page View:24247
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In